If a telehealth site or a med spa has offered you "tirzepatide" in a vial, the word on the label matches the word on a Zepbound pen. FDA says they are not the same thing. Compounded drugs are not generics, and in February 2026 the agency said that, in promotional materials, companies cannot claim that non-FDA-approved compounded products are generic versions or the same as approved drugs.
What compounded tirzepatide is
Tirzepatide is the active ingredient in two FDA-approved Eli Lilly medicines. Mounjaro is approved for blood sugar control in type 2 diabetes. Zepbound is approved, with diet and exercise, for weight reduction in adults with obesity, or overweight plus a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity.
A compounded version is mixed by a pharmacy or an outsourcing facility, and FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. A generic, by contrast, is FDA-approved and has to establish therapeutic equivalence to the brand, according to the agency's compounding Q&A.
State-licensed pharmacies compound under section 503A of the Federal Food, Drug, and Cosmetic Act and are overseen mainly by state boards of pharmacy. Outsourcing facilities register with FDA under section 503B, are inspected by FDA on a risk-based schedule and must follow current good manufacturing practice rules, which 503A pharmacies don't.
Why pharmacies could copy it
Tirzepatide injection had been in shortage since 2022 because of increased demand. A shortage changes the rules. Normally compounders can't regularly make essentially copies of an approved, available drug. While the approved drug is on FDA's drug shortages list, some of those limits may not apply (other conditions still do), and an outsourcing facility can make it from a bulk drug substance.
The shortage ended in steps, per FDA's page clarifying its policies for compounders:
- October 2, 2024: FDA determined the tirzepatide shortage was resolved. On October 22, as part of litigation, that decision went back to FDA for reevaluation.
- December 19, 2024: FDA issued a new decision that the shortage is resolved, with grace periods until February 18, 2025, for 503A pharmacies and March 19, 2025, for 503B outsourcing facilities.
- February 11, 2025: FDA said each period would last until that date or a court ruling on a preliminary injunction in the lawsuit, whichever came later.
- March 5, 2025: a federal court in Texas denied it in Outsourcing Facilities Association v. FDA. On March 10, FDA said the 503A grace period had ended; the 503B one ran to March 19, 2025.
Where things stand in November 2026
On April 1, 2026, FDA reminded compounders of the conditions they must meet. For outsourcing facilities it's short: a 503B facility can only compound from bulk ingredient if the substance is on the 503B bulks list or the drug is on the shortage list, and FDA says tirzepatide is currently on neither.
For 503A pharmacies, the drug must be compounded for an individual patient based on a prescription, and the pharmacy can't compound essentially copies of a commercially available drug regularly or in inordinate amounts. FDA counts a product as essentially a copy if it has the same active ingredient in a same, similar or easily substitutable strength, given the same way, unless a prescriber determines and documents a change that produces a significant difference for an identified individual patient. At this time, FDA says it doesn't intend to act against a compounder that fills four or fewer prescriptions of such a product in a calendar month.
I'm not a lawyer, and I can't tell you whether any particular prescription meets these conditions. The page is clear on who decides, though: a prescriber, documenting a significant difference for one identified patient.
On February 6, 2026, FDA said it intends to restrict GLP-1 active ingredients meant for non-approved compounded drugs mass-marketed as similar alternatives to approved drugs. Its concerns page, current as of October 1, still says compounded drugs should only be used in patients whose medical needs can't be met by an FDA-approved drug.
The risks FDA has documented
Units, milligrams and syringes
Approved tirzepatide is dosed in milligrams: Zepbound starts at 2.5 mg a week and tops out at 15 mg. It also comes in vials, and its label calls for a syringe appropriate for the dose, such as a 1 mL syringe that can measure a 0.5 mL or 0.6 mL dose.
With compounded semaglutide, FDA found that vials added a conversion step. Its 2024 alert described instructions written in "units" instead of milligrams, syringes much larger than the prescribed volume, and patients who drew up five to 20 times the intended dose. A 2023 poison center case series describes three people using compounded semaglutide from compounding pharmacies and an aesthetic spa. Two made 10-fold dosing errors, and all three had nausea, vomiting and abdominal pain. Three cases can't show how common this is, only how it happens.
Both reports are about semaglutide. For tirzepatide, FDA's concerns page says it has received adverse event reports that may be related to compounded semaglutide or tirzepatide prescribed beyond the label (more per dose, more often, or stepped up faster), and asks patients to check with their provider or compounder how to measure the intended dose. I'd apply the semaglutide lesson to any vial.
Adverse event reports
As of May 31, 2026, FDA had received more than 730 adverse event reports associated with compounded tirzepatide. FDA says these are likely underreported, because 503A pharmacies don't have to send them, and that a report doesn't always show the drug caused the problem. It also says many of the reported events appear consistent with those seen with the approved versions.
A 2025 analysis of FDA's adverse event database (2018 to 2024) pooled liraglutide, semaglutide and tirzepatide: 707 of 81,078 GLP-1 reports involved compounded products. Those had higher reporting odds of hospitalization (2.35), contamination, and preparation or prescribing errors, but lower odds of dosing and administration errors. The abstract gives no tirzepatide-only figures, and the study wasn't designed to show cause and effect.
Added ingredients
FDA's 2024 alert said some compounders add B12, B6, L-carnitine or NAD to semaglutide, and that the safety and effectiveness of those combinations hasn't been established. A 2026 secret shopper study of 75 weight-loss clinics and medical spas in West Virginia and Oklahoma, done after the shortages ended, found 42 (56.0%) offering compounded GLP-1 products with B vitamins, and 4 of 21 supplier facilities assessed weren't licensed for sterile compounding. The states were picked for likely high demand, so they may not reflect others.
A 2026 lab study of compounded tirzepatide and B12 samples reported a previously unidentified impurity formed by a reaction between tirzepatide and certain B12 analogs. The abstract says it was present at "substantial levels" but not how many samples were tested, and its clinical effects are unknown. All five authors work for Eli Lilly, which sells the approved versions and so has a stake in the answer.
Fakes, "research use" and storage
- FDA knows of fraudulent compounded tirzepatide labeled with pharmacies that don't exist or didn't make it.
- FDA has warned companies selling consumers tirzepatide falsely labeled "for research purposes" or "not for human consumption", and urges people not to buy it.
- FDA has had complaints of compounded GLP-1 drugs arriving warm and says not to use any that do.
- FDA recommends discarding a multiple-dose vial within 28 days after first use, even if medication remains or the compounder's instructions say longer.
What the approved drug's evidence covers
SURMOUNT-1, published in the New England Journal of Medicine in 2022, randomly assigned 2,539 adults with obesity, or overweight plus a weight-related complication (diabetes excluded), to weekly tirzepatide at 5, 10 or 15 mg or placebo for 72 weeks. Average weight change was -15.0%, -19.5% and -20.9% on the three doses, against -3.1% on placebo. The most common side effects were gastrointestinal, and most were mild to moderate. Eli Lilly funded it.
It's a large, long, double-blind trial, but no compounded product was in it, so it can't tell you whether a given vial performs the same.
Some label warnings are about tirzepatide itself, and I'd read them as applying to anyone injecting it:
- A boxed warning: tirzepatide causes thyroid C-cell tumors in rats, and it's unknown whether it causes them in humans, including medullary thyroid carcinoma (MTC). It is contraindicated with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2.
- It may reduce the efficacy of birth control pills. The labels advise switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. See tirzepatide and oral contraceptives.
- With insulin or an insulin secretagogue such as a sulfonylurea, it may raise the risk of hypoglycemia, including severe hypoglycemia. See tirzepatide with insulin and with glipizide.
- The Zepbound label says it may cause fetal harm, that it should be discontinued when pregnancy is recognized, and asks patients to tell their healthcare provider if they are pregnant or intend to become pregnant.
The Zepbound label also says combining it with other tirzepatide-containing products or any GLP-1 receptor agonist is not recommended.
What to check and ask
- Ask whether the product is FDA-approved or compounded. FDA calls it a red flag when a company claims its compounded drug is the same as an approved one.
- Ask which pharmacy made it. FDA notes that people buying online may not know who compounded their drug.
- Look that pharmacy up through your state board of pharmacy. FDA's BeSafeRx page links to each state's license database and says not to use an online pharmacy that isn't listed.
- If it's an outsourcing facility, find it on FDA's list of registered 503B facilities, which shows the last inspection and whether a Form 483 was issued.
- Ask what's in the vial besides tirzepatide, and for your dose in milligrams plus the matching units on the syringe you were sent.
- Ask who answers questions after the package arrives. FDA flags companies with no licensed doctor available afterward.
- Report problems to FDA's MedWatch program.
None of this is a reason to start, stop or switch anything on your own. If something here worries you, bring the vial, the syringes and the instructions to your prescriber or a pharmacist. Pilora's interaction checker includes tirzepatide, so you can see it next to everything else you take.
The bottom line
Compounded tirzepatide is not a generic Mounjaro or Zepbound. FDA hasn't reviewed it, SURMOUNT-1 didn't test it, and the shortage-era grace periods ended in March 2025. If you use it or were offered it, go over it with your prescriber and a pharmacist, especially if you take birth control pills, insulin or a sulfonylurea, are pregnant or planning a pregnancy, or have a personal or family history of medullary thyroid cancer.
